solid rais
revenu beat driven symdeko ep beat
management rais revenu guidanc strong
smydeko trajectori cf tripl enrol timelin point
revenu posit updat expect upward
pressur
ep beat revenu beat vs con
grew y/i note product level cf consensu figur hard compar
given orkambi estim includ symdeko management rais full-year cf
product revenu guidanc includ kayldeco
orkambi symdeko maintain full-year non-gaap combin
sg expens
takeaway call symdeko strong demand earli trend
indic favor persist complianc demand particularli
strong among homozyg patient initi treatment first
time also prior orkambi discontinu management rais guidanc base
symdeko launch current midpoint impli growth
two tripl program proceed rapidli phiii enrol
complet expect nda file later
crispr gene edit drug cta approv uk
canada trial initi beta-thalassemia set year management current
answer fda question regard ind clinic hold would
detail specif concern express fda continu believ either
relat question around specif site chosen
edit data neuropath pain remain track earli
solid symdeko continu tripl momentum meet investor expect
overal quarter clean strong revenu growth although
symdeko beat partial off-set declin orkambi result
patient switch given continu strength franchis
increas estim toward high-end management rang
continu see well posit although next coupl quarter
larg symdeko execut stori enrol complet tripl
combo studi later year ahead data
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
triplet approv
triplet approv uptak life-cycl manag oper margin drive
uptak life-cycl manag oper margin drive
penetr across cf medicin life-cycl extens extend
franchis bull case assum higher penetr tripl
therapi het/min homozygot patient initi tripl data
replic phiii therapi launch ww sale
het/min homozygot addit tripl data commerci
success key
risk-adjust tripl combo success mainten key cf franchis
life-cycl extens base case assum penetr orkambi
homozyg cf patient eventu switch captur
homozyg het/min market tripl combo risk-adjust peak ww sale
tripl combin therapi
modest orkambi uptak tripl combin fail achiev approv
het/min popul bear case assum row us
penetr orkambi homozyg cf patient peak ww sale
kalydeco monotherapi peak
overweight vertex believ
initi tripl data replic phiii
studi see vertex clear leader
cf therapi beliv management potenti
deliv ep overtim
initi phi phii data tripl
het/min popul better
kalydeco-lin efficaci
homozyg popul thu includ
risk-adjust tripl combin revenu
base case
believ potenti
competit believ vertex
signific advantag posit
on-market doubl combin in-
share competitor long-
main driver vertex phiii
tripl studi time approv launch
uptak current therapi
orkambi/kalydeco/symdeko uptak
risk achiev price
combo penetr fall short
kalydeco/orkambi/symdeko sale fail
meet expect
data clinic candid
tripl combin fail meet expect
data competit exce
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
import us regulatori disclosur subject compani
june benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur amgen inc avrobio inc beigen
within last month receiv compens invest bank servic amgen inc avrobio inc beigen ltd
next month expect receiv intend seek compens invest bank servic
within last month receiv compens product servic invest bank servic amgen inc
within last month provid provid invest bank servic invest bank client relationship
follow compani amgen inc avrobio inc beigen ltd biogen inc
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amgen inc biogen inc
 co llc make market secur amgen inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
